The Latest Cardiac and Vascular News
PRINCETON, N.J., April 20, 2023 (GLOBE NEWSWIRE) — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that its pivotal STAR-T (Safe and Timely Antithrombotic Removal – Ticagrelor) randomized, controlled trial has enrolled 80 patients, […]
The HeartPlace partnership represents USHV’s 6th in Texas and 1st in Dallas-Fort Worth. NASHVILLE, Tenn.–(BUSINESS WIRE)–US Heart & Vascular (“USHV”), a leading national provider of support services to cardiovascular physician practices, has partnered with HeartPlace (“HeartPlace”), the largest physician-owned cardiology practice in Texas, focused on all aspects of cardiovascular care. “We […]
In a study assessing high-risk heart donors at the 43rd ISHLT Annual Meeting & Scientific Sessions, GUARDIAN-Heart Registry data indicates a significant reduction in Primary Graft Dysfunction (PGD), a severe post-transplant complication, potentially allowing for an increase in donor hearts available for heart transplant patients. CAMBRIDGE, MASSACHUSETTS, April 20, 2023 […]
Use of artificial intelligence technology efficiently identifies eligible patient candidates for pivotal clinical trial; program launched at The Christ Health Network SANTA CLARA, Calif. & ALISO VIEJO, Calif.–(BUSINESS WIRE)–Ancora Heart, Inc., a medical device company developing a novel transcatheter device-based therapy to address heart failure (HF), and egnite, Inc., a leading digital health […]
– Performance-Based Agreement Provides for Currax’s 72 Sales Representatives to Detail Esperion’s Products – – Reinforces Esperion’s Focus on Driving Persistent Growth By More Than Doubling Sales Team – ANN ARBOR, Mich., April 19, 2023 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced an agreement with Currax Pharmaceuticals LLC that provides for all of […]
Non-invasive, AI-enabled product helps CT readers to accurately*, efficiently, and consistently identify narrowings in the coronary arteries, advancing the HeartFlow portfolio MOUNTAIN VIEW, Calif., April 17, 2023 (GLOBE NEWSWIRE) — HeartFlow, Inc. today announced the launch of the RoadMap analysis, a new AI-enabled product that assists CT readers to accurately*, […]
Hoag is one of the first three sites in the nation enrolling patients in a post-market study Hoag cardiac surgeons are among an elite class of specialists experienced with this latest generation valve option Study expected to grow to include centers around the world NEWPORT BEACH, Calif., April 17, 2023 /PRNewswire/ — […]
Compounds that activate SERCA2a may lead to novel therapies for heart failure WARRINGTON, Pa., April 17, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced that the European Patent Office has granted Patent […]
HOUSTON–(BUSINESS WIRE)–IPS HEART has been granted rare pediatric drug designation by the FDA for GIVI-MPC, a first-in-class stem cell therapeutic to create new skeletal muscle with 100% full length dystrophin and for ISX9-CPC, a first-in-class stem cell therapeutic for creating new functional cardiac muscle for the treatment of patients with Duchenne […]
WASHINGTON, April 11, 2023 /PRNewswire/ — A first-of-its-kind study has established pediatric reference intervals for two common tests for cardiovascular disease. Published in AACC’s The Journal of Applied Laboratory Medicine, these findings are crucial to advancing diagnosis and treatment of heart conditions in children. View the full study here: https://doi.org/10.1093/jalm/jfad012 Many pediatric hospitals have started […]
